📰 Mark Sumeray News
Mark Sumeray News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Mark Sumeray. Real-time updates on events, politics, business and more.
May 2, 2024
Eneboparatide is an investigational parathyroid hormone receptor 1 (PTHR1) agonist that works by binding with high affinity to a specific conformation of the PTH1 receptor.
June 7, 2023
Amolyt Pharma to Host Hybrid Key Opinion Leader Event on Eneboparatide, a PTHR1 Agonist Entering Phase 3 for the Treatment of Hypoparathyroidism, in Chicago on June 16, 2023LYON, France and CAMBRIDGE, Mass., June 07, 2023 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic pepti...
June 7, 2023
LYON, France and CAMBRIDGE, Mass., June 07, 2023 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced
June 5, 2023
LYON, France and CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today
May 11, 2023
Presentation highlights results from 13- and 39-week studies of eneboparatide in non-human primates demonstrating no evidence of deleterious impact on bone quantity or quality as measured by multiple bone
October 12, 2022
93% of patients in Cohort 2 discontinued both active vitamin D and oral calcium supplementation, while maintaining mean serum calcium within the target range Mean 24-hour urinary calcium was rapidly
October 12, 2022
Data from cohort 2 and full Phase 2a clinical trial to be presented at the 38th Congress of the French Society of Endocrinology and 2022 International HypoPARAthyroidism ConferenceLYON, France and CAMBRIDGE
September 7, 2022
KOL event to follow company's presentation at the American Society for Bone and Mineral Research (ASBMR) 2022 Annual MeetingLYON, France and CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Amolyt
September 7, 2022
Investegate announcements from Amolyt Pharma, Amolyt Pharma to Host Hybrid Key Opinion Leader Event on its Potential Hypoparathyroidism Treatment, AZP-3601, on Monday, September 12th at 1:30pm CT/2:30pm ET in Austin, Texas
September 7, 2022
KOL event to follow company’s presentation at the American Society for Bone and Mineral Research (ASBMR) 2022 Annual Meeting...